SCHEMBL4923600

SCHEMBL4923600

CN(Cc1ccc(F)cc1)S(=O)(=O)c1ccc(CN2CCNCC2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 3/20 0.62
NR1H2 P55055 1/20 0.59
MLNR O43193 1/20 0.53
HTR6 P50406 1/20 0.51
MAOA P21397 2/20 0.49
MAOB P27338 1/20 0.49
CASP3 P42574 1/20 0.49
HTR2C P28335 1/20 0.46
KMT2A Q03164 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
LSS P48449 1/20 0.44
CCR2 P41597 2/20 0.43
MEN1 O00255 2/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
ADRA2C P18825 1/20 0.43
CXCL12 P48061 1/20 0.43
BLM P54132 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4924436 0.89 CXCR4 (0.79) CXCR4NR1H2HTR2CKMT2ALMNA
SCHEMBL14045873 0.89 CXCR4 (0.55) CXCR4NR1H2MLNRHTR6MAOA
SCHEMBL11342016 0.78 SIGMAR1 (0.66) CXCR4HTR6KMT2ACCR2MEN1
SCHEMBL211040 0.78 SIGMAR1 (0.66) CXCR4HTR6KMT2ACCR2MEN1
SCHEMBL4913576 0.78 CXCR4 (0.69) CXCR4NR1H2HTR2CKMT2ALMNA
SCHEMBL4743408 0.77 CXCR4 (0.61) CXCR4NR1H2HTR6HTR2CKMT2A
SCHEMBL4923100 0.77 CXCR4 (1.00) CXCR4KMT2ALMNAMEN1HRH3
Hydrochloric Acid SCHEMBL3062972 0.77 CXCR4 (0.66) CXCR4HTR6KMT2ACCR2MEN1
Hydrochloric Acid SCHEMBL6291076 0.77 CXCR4 (0.66) CXCR4HTR6KMT2ACCR2MEN1
SCHEMBL4923111 0.76 CXCR4 (1.00) CXCR4KMT2ALMNAMEN1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A CXCR4 242/4885NR1H2 3154/4885MLNR 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.